Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q3 2024 · 10-Q
Revenue$2.73M$2.73M−33.2% vs Q3 2023 Net Income-$164.25M-$164.25MN/M vs Q3 2023 EPS Diluted-$0.86-$0.86N/M vs Q3 2023 Operating Income-$191,750,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$180,703,000N/M Margins · derivedOperating margin-7018.7%−3164.1 pt vs Q3 2023
Net margin-6012.2%−1624.8 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end